The National Institute for Health and Clinical Excellence (NICE) issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on preoperative high dose rate brachytherapy for rectal cancer in December 2006. In accordance with the Interventional Procedures Programme Process Guide, guidance on procedures with special arrangements are reviewed 3 years after publication and the procedure is reassessed if important new evidence is available.
The guidance was considered for reassessment in October 2010 and it was concluded that NICE will not be updating this guidance at this stage. However, if you believe there is new evidence which should warrant a review of our guidance, please contact us via the email address below.
Rectal cancer is a common form of bowel cancer. Preoperative high dose rate brachytherapy involves placing radioactive material in or close to the tumour to shrink it before surgery.
X65.2 Delivery of a fraction of intracavitary radiotherapy
Note: Use a subsidiary code to identify introduction of radioactive material (Y35, Y36)
Y35.8 Other specified introduction of removable radioactive material into organ NOC
Y89.1 High dose rate brachytherapy treatment
In addition the ICD-10 code C20.X Malignant neoplasm of rectum or C78.5 Secondary malignant neoplasm of large intestine and rectum is assigned
The NHS Classifications Service of the Health and Social Care Information Centre is the central definitive source for clinical coding guidance and determines the coding standards associated with the classifications (OPCS-4 and ICD-10) to be used across the NHS. The NHS Classifications Service and NICE work collaboratively to ensure the most appropriate classification codes are provided. http://systems.hscic.gov.uk/data/clinicalcoding